toggle mobile menu Menu
toggle search menu

Site Navigation

Supplemental

Menu

Blog Post

St. Luke's Blogs

St. Luke’s Responds to Expanded Meningitis Related Recall

By Ken Dey, News and Community
October 17, 2012

St. Luke’s Health System has not received any of the potentially tainted spinal steroid injections made by the New England Compounding Center (NECC). The injections are linked to a recent national outbreak of meningitis.

On Wednesday, October 17, the Food and Drug Administration (FDA) released a new advisory recommending that all health organizations remove any product purchased from NECC not just spinal steroid injections.

While NECC is not a permanent St. Luke’s vendor, between July and October of this year, St. Luke’s purchased products from the company to offset a shortage in the market. Since learning of these quality issues, St. Luke’s has terminated its relationship with the company.

Prior to the latest FDA recommendations, St. Luke’s has removed all products obtained from NECC. As a precaution, St. Luke’s is now in the process of identifying patients who may have received an NECC product.

At this time, the FDA said that no illnesses have been associated with the products identified in the expanded recall. While we see no indication that any St. Luke’s patients are at risk, we recognize the need to be proactive. Patients who receive a notification and have any questions or concerns should contact their primary care provider.

St. Luke’s will continue to monitor the situation and provid any updates to patients affected by this recall.

For more information about the recall please visit the following Web sites:

Centers for Disease Control and Prevention

 U.S. Food and Drug Administration

-end-

For more information, contact St. Luke’s Media Manager, at (208) 381-2894

 

About The Author

Ken Dey served as Public Relations Coordinator at St. Luke's from 2008-2014.